Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor
Antoinette R. Tan, Xiaowei Yang, Stephen M. Hewitt, Arlene Berman, Erin R. Lepper, Alex Sparreboom, Allyson L. Parr, William D. Figg, Catherine Chow, Seth M. Steinberg, Stephen L. Bacharach, Millie Whatley, Jorge A. Carrasquillo, Jaime S. Brahim, Seth A. Ettenberg, Stan Lipkowitz, Sandra M. Swain*
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
165
Scopus
citations